Q-omics provides the consensus-scored MIR6077 profile across patient tissues and cancer cell-line models. MIR6077 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, MIR6077 is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, MIR6077 RNA expression shows 8,714 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight LUAD, THCA, and LIHC as cancer lineages where MIR6077 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6077 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6077 survival associations across molecular data types. MIR6077 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6077 RNA expression–survival associations across cancer types. High MIR6077 expression shows unfavorable associations in LUAD, KIRP, KIRC, HNSC, CHOL and DLBC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for MIR6077 RNA expression.
This table summarizes MIR6077 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6077. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6077 shows lower tumor expression in THCA and higher tumor expression in BLCA, LUAD and UCEC. The THCA box plot shows higher MIR6077 RNA expression in normal versus tumor tissue (log2 FC = −0.453, t-test p < 0.001).
This table shows molecular features associated with MIR6077 in patient tissues and cancer cell lines. In patient samples, MIR6077 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
